|
In general terms, malfunctioning of epigenetic mechanisms regulating gene expression leads to diseases such as neoplastic transformation. Biomarker assays targeting disease related epigenetic changes can effectively be utilized as biomarkers at all stages of clinical disease management, from risk assessment, through early diagnosis and treatment personalization, to post treatment surveillance. Recently, large-scale clinical trials have shown that methylation biomarker-based cancer detection in liquid biopsies allows early detection of cancer in patients with remarkable specificity and sensitivity Specifically, detection of BRCA1 gene methylation in blood has been proposed as a biomarker of predisposition to breast and ovarian cancers. Additionally, methylation of the MGMT gene has long been used to guide treatment of glioblastoma multiforme patients. And recently, the genome wide profiling methylation has been suggested by the WHO as an alternative to standard histopathology for the classification of brain tumors. In my talk I will review recent developments in methylation biomarker research and applications of epigenetic biomarkers in clinical disease management.
Presented by: Prof. Dr. Tomasz K. Wojdacz
Topic: Epigenetics, Clinical |
 |
|
Understanding the histopathology of COVID-19 has proven to be a major gateway to understanding the molecular mechanisms through which SARS-CoV-2 manifests disease. The group of Dr. Nuovo has contributed significantly to understanding the pathophysiology of severe COVID-19 and utilized Enzo’s AMPIVIEW SARS-CoV-2 RNA probes kit in the process. He will present the highlights of his group’s findings in Enzo’s webinar series. Amongst them: 1. Detection of SARS-CoV-2 RNA in situ shows that productive infection predominates in the nasopharynx and lung; 2. Detection of SARS-CoV-2 proteins (nucleocapsid, spike, envelope and matrix) show that spike is avidly endocytosed via the vascular system in several sites, including the brain and heart; viral RNA is rarely evident in these sites; 3. Correlation of the host response to the in situ localization of SARS-CoV-2 RNA and spike protein shows that each are associated with increased expression of proinflammatory proteins including TNFa and IL6 as well as complement activation.
Main Target Audience: Pathophysiologists; Clinical Laboratories; Hospitals; Histologists; Virologists - Researchers interested in the following topics: Coronavirus, in situ Hybridization (ISH); Antibodies; Clinical Diagnostics; DNA/Protein Labeling, HPV, Immunohistochemistry (IHC), Immunology, Inflammation, Pathology, Virology. Why should you attend?: Whether you are a scientist, a student, a lab technician, or a curious citizen, this webinar will provide fascinating mechanistic insight into the pathophysiology of severe COVID-19, while simultaneously providing a wealth of practical knowledge on the laboratory technologies utilized in detecting viral RNA and proteins, especially in situ hybridisation and immunohistochemistry. Presented by: Dr. Gerard J. Nuovo
Topic: Clinical |
 |
